English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

It is estimated that 415 million people have diabetes worldwide1. It is expected to rise to 592 million in 20352. Diabetes mellitus is not only chronic disease, but also brings a variety of complications, such as diabetic retinopathy. The glucagon-like peptide 1 receptor agonists (GLP-1 RAs) mimic the effects of endogenous GLP-1 hormone, stimulate insulin secretion and suppress glucagon secretion (in a glucose-dependent manner). GLP-1 RAs manage glycemic condition and stimulate satiety, as a result reducing food intake and body weight3. Currently, there are two types of GLP-1 RAs namely short-acting (such as exenatide, lixisenatide) and long-acting (such as liraglutide, dulaglutide, semaglutide) for the treatment of type 2 diabetes mellitus (T2DM). Subcutaneous semaglutide is a new

Efficacy and safety of semaglutide in type 2 diabetes compared with sitagliptin, exenatide ER, insulin glargine, basal insulin and placebo: a systematic review